Patient Presents With an Enlarged Prostate

Poll

A 54-year-old man is found to have an enlarged prostate. Based on the biopsy shown, what is your diagnosis?

A 54-year-old man is found to have an enlarged prostate.

Based on the biopsy shown, what is your diagnosis?

A. High-grade prostatic adenocarcinoma
C. Small-cell carcinoma
D. Transitional cell carcinoma
B. Rhabdomyosarcoma of the prostate
Recent Videos
Considering which non–muscle-invasive bladder cancer cases may be cured by surgery alone may help mitigate overtreatment in this patient group.
Treatment of Earlier-Stage Disease May Strengthen NMIBC-Related Survival
Event-free survival benefit was observed among BCG-naïve patients with carcinoma in situ undergoing treatment with sasanlimab plus BCG.
Sasanlimab Combo Improves EFS “Across the Board” in BCG-Naive NMIBC
Various methods of communication ensure that members from radiation oncology, pathology, and other departments are on the same page regarding treatment.
Making a ‘World of Difference’ Via Multidisciplinary Care in GI, GU Cancers
Comprehensive prehabilitation may help prepare patients for bladder-preserving surgery, helping to optimize quality of life outcomes.
Reviewing QOL Strategies/Considerations Following Bladder Cancer Surgery
Ongoing research suggests environmental exposures and the role of microbiomes may influence bladder cancer development and response to treatment.
Outlining Risk Factor Identification and Mitigation in Bladder Cancer
How a Radiation Oncologist Answers Patient Questions with Research
How a Radiation Oncologist Answers Patient Questions with Research
There Is Excitement and Advances in SBRT Treatment For RCC
There Is Excitement and Advances in SBRT Treatment For RCC
Radiation Oncology in Prostate Cancer Is Advancing Thanks to Technology and Time
Radiation Oncology in Prostate Cancer Is Advancing Thanks to Technology and Time
Strong Collaboration is Essential for Radiation Oncologists and Other Experts
Strong Collaboration is Essential for Radiation Oncologists and Other Experts
The Effect of Dato-DXd Targeting TROP2 in Urothelial Cancer
The Effect of Dato-DXd Targeting TROP2 in Urothelial Cancer
Related Content
The FDA did not expand the indication to include patients with non-homologous recombination-repair gene-mutated castration-resistant prostate cancer.

FDA Accepts sNDA for Talazoparib/Enzalutamide in HRR-Mutant mCRPC

Roman Fabbricatore
June 18th 2025
Article

The FDA did not expand the indication to include patients with non–homologous recombination repair gene mutated castration-resistant prostate cancer.

A Sneak Peek at 2025 ASCO From the GU Perspective

A Sneak Peek at 2025 ASCO From the GU Perspective

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
May 15th 2025
Podcast

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, highlight exciting trials in the genitourinary cancer space expected to be presented at 2025 ASCO.

The addition of CAN-2409 to a prodrug and radiation therapy in intermediate-to-high-risk prostate cancer significantly improved cancer-specific outcomes.

CAN-2409/EBRT Improves Disease-Free Survival in Localized Prostate Cancer

Roman Fabbricatore
June 3rd 2025
Article

The addition of CAN-2409 to a prodrug and radiation therapy in intermediate-to-high-risk prostate cancer significantly improved cancer-specific outcomes.

Leaders in genitourinary oncology spoke about key research advances as well as personal experiences in navigating the field.

Finding Ways to Break the Mold in GU Oncology

Maha H. Hussain, MD;Sarah E. Fenton, MD, PhD
April 8th 2024
Podcast

Leaders in genitourinary oncology spoke about key research advances as well as personal experiences in navigating the field.

Eight votes were cast against the favorability of talazoparib and enzalutamide in the first-line setting for patients with metastatic castration-resistant prostate cancer.

ODAC Votes 8-to-0 Against First-Line Talazoparib/Enzalutamide in mCRPC

Roman Fabbricatore
May 21st 2025
Article

Eight votes were cast against the favorability of talazoparib and enzalutamide in the first-line setting for patients with metastatic castration-resistant prostate cancer.

Data from the LITESPARK-015 trial supported the FDA’s decision to approve belzutifan monotherapy in patients with advanced, unresectable, or metastatic PPGL.

FDA Approves Belzutifan in Adult/Pediatric Pheochromocytoma and Paraganglioma

Tim Cortese;Ariana Pelosci
May 14th 2025
Article

Data from the LITESPARK-015 trial supported the FDA’s decision to approve belzutifan monotherapy in patients with advanced, unresectable, or metastatic PPGL.